Interaction at dopamine D 4 receptors may improve cognitive function, which is highly impaired in individuals with schizophrenia, but comparative studies of recent antipsychotics in cellular models of D 4 receptor activation are lacking. Here, we report the in-vitro profile of over 30 ligands at recombinant hD 4.4 receptors. In [
Introduction
Schizophrenia patients suffer from a panoply of symptoms, clinically differentiated into positive and negative symptoms as well as cognitive deficits that are only partially responsive to current antipsychotic therapies. In particular, cognitive dysfunction (working and reference memory deficits, perseveration, decreased vigilance, impaired executive function) represents an obstacle to functional recovery and social integration. Whilst conventional antipsychotics such as haloperidol, acting primarily via blockade of dopamine D 2 /D 3 receptors, alleviate positive symptoms, they fail to counter negative symptoms or cognitive deficits (Goldberg and Green, 2002 ; Harvey and Davidson, 2002 ; Meltzer et al., 1999) . 'Atypical ' antipsychotics, such as clozapine, olanzapine and risperidone, antagonize D 2/3 receptors but also act at a variety of other receptors, including several serotonin receptor subtypes. Indeed, combined blockade of D 2 and 5-HT 2 receptors is associated with reduced extrapyramidal symptoms and increased frontal cortex dopamine levels, a marker of efficacy against negative symptoms/cognitive deficits (Meltzer et al., 2003) .
Recently, a 'third generation ' of potential antipsychotics has attracted increasing attention, by targeting D 2 -like receptors as well as acting as serotonin 5-HT 1A receptor agonists. Such drugs include aripiprazole, bifeprunox, SSR181507, SLV313, RGH188 and F15063 (Claustre et al., 2003 ; Kiss et al., 2006 ; McCreary et al., 2007 ; Newman-Tancredi et al., 2007 ; Shapiro et al., 2003 ; Wadenberg, 2007) . Previous studies have demonstrated that such compounds exhibit varying levels of antagonist or partial agonist properties at D 2 receptors in vitro in measures of G-protein activation at hD 2L receptors (Cosi et al., 2006) , phosphorylation of extracellular-regulated kinase (ERK1/2) phosphorylation at hD 2S receptors (Bruins Slot et al., 2006) , and activation of G-proteincoupled inwardly rectifying potassium (GIRK) currents in Xenopus oocytes transfected with hD 2L receptors (Heusler et al., 2007) . Further, thirdgeneration antipsychotics also display diverse influence on activation of D 3 receptors (Bruins .
Many antipsychotics also bind with high affinity to D 4 receptors (Leysen, 2000 ; Newman-Tancredi et al., 1997a ; Van Tol et al., 1991) . Indeed, interest in this receptor subtype was stimulated by the observation that clozapine has slightly higher affinity, and antagonist properties, at this receptor than for D 2 or D 3 receptors (Leysen, 2000 ; Van Tol et al., 1991) , suggesting that aspects of clozapine's 'atypical ' profile may be attributed to actions at the D 4 receptor. However, clinical trials showed that positive symptoms of acutely psychotic schizophrenics were not diminished by selective D 4 receptor antagonists (Bristow et al., 1997 ; Corrigan et al., 2004) or combined D 4 /5-HT 2A antagonism (Truffinet et al., 1999) . Thus, the role of D 4 receptor interaction in the profile of antipsychotics remains open to discussion and recent evidence from rodent pharmacological models has pointed to the involvement of D 4 receptors in the regulation of cognition :
(i) D 4 receptors are preferentially localized in brain regions that are implicated in regulation of memory and cognitive function, including the hippocampus and frontal cortex, where they are located on GABAergic neurons (Mrzljak et al., 1996) . In contrast, D 4 receptors are not expressed in brain regions associated with motor or endocrine side-effects, such as the basal ganglia or pituitary gland (De la Garza and Madras, 2000 ; MeadorWoodruff et al., 1996 ; Primus et al., 1997 ; Wong and Van Tol, 2003 (Wang et al., 2003) , consistent with an influence on a brain region of key importance in cognitive function. The same authors also showed that in-vivo treatment of rats with phencyclidine (PCP), a drug that provokes psychotic-like symptoms in humans, disrupts D 4 receptor control of NMDA receptor-mediated currents, an effect that could be reversed by clozapine (Wang et al., 2005) . (iii) D 4 receptor blockade has protective properties on cultured hippocampal neurons (Bastianetto et al., 2006) . In comparison, D 4 receptor activation reduces oxidative stress induced in rat cortical neurons (Ishige et al., 2001 (Bernaerts and Tirelli, 2003) , short-term social memory (Browman et al., 2005) and increased exploratory activity (Powell et al., 2003) . In contrast, in tests of cognition in primates, D 4 receptor antagonists opposed the deficits in frontal cortex-dependent working-memory tasks induced by stress (Arnsten et al., 2000) or chronic treatment with PCP (Jentsch et al., 1999) . The issue of the balance of activation or blockade of D 4 receptors necessary for beneficial properties on cognition was discussed by Zhang et al. (2004) who observed that a D 4 receptor antagonist, L745870, had differential effects in rats with high vs. low basal memory performance, suggesting that optimal responses may be obtained with a partial agonist. (v) D 4 receptor knock-out mice exhibit hypersensitivity to psychostimulants (Rubinstein et al., 1997) and D 4 receptors are also implicated in deficits in attentional processing, with gene association studies showing that D 4 gene expression is associated with attention deficit hyperactivity disorder (ADHD ; Faraone and Khan, 2006 ; Waldman and Gizer, 2006) . Thus, targeting of D 4 receptors provides a potential strategy to manage ADHD, possibly via inhibition of GABA release in the subthalamic nucleus (Floran et al., 2004) . In rats with neonatal 6-hydroxydopamine lesions, an animal model of ADHD, a D 4 antagonist attenuated whereas a D 4 agonist accentuated the hyperactivity observed in adulthood (Avale et al., 2004 ; Zhang et al., 2001 ). (vi) In humans, D 4 receptors are up-regulated in schizophrenics, independently of their antipsychotic treatment, suggesting that the changes are disease-related (Lahti et al., 1998) . D 4 receptor activation is also relevant to the treatment of sexual dysfunction, a frequently reported side-effect of antipsychotic treatment that can seriously influence treatment outcome in schizophrenia patients (Chue, 2006 ; Ü çok et al., 2007) . Compounds possessing D 4 agonist properties, such as ABT724 and flibanserin (a compound also possessing 5-HT 1A receptor agonist activity), are in clinical evaluation for sexual dysfunction (Borsini et al., 2002 ; Brioni and Moreland, 2006 .
Methods

Binding affinity at dopamine hD 4.4 receptors
The D 4.4 isoform (four-repeat sequence) of D 4 receptors was examined in the present study because it is the most widely expressed allele in humans (Chang et al., 1996) and reagents were incubated for 60 min at 22 xC before rapid filtration and scintillation counting. Non-specific binding was defined with GTPcS (10 mM). Efficacy of agonists was expressed in comparison with that of dopamine (10 mM) that was tested in parallel in each experiment and defined as 100 % (basal activity was defined as 0 %). In the case of antagonist experiments, the compounds were pre-incubated with CHO-hD 4.4 membranes, as above, before addition of dopamine (1 mM 
Xenopus laevis oocyte expression
The plasmid containing the coding sequence for the human D 4.4 receptor was subcloned into the Xenopus high expression vector pGEMHE (Liman et al., 1992) and designated pGEMHE/hD 4.4 . Plasmids pSP/ GIRK1 and pBScMXT/GIRK2 encoding the GIRK1 and GIRK2 potassium channel subunits were prepared as described (Heusler et al., 2005) . Plasmids were linearized with NheI (pGEMHE/hD 4.4 ), EcoRI (pSP/GIRK1) or SalI (pBScMXT/GIRK2) and invitro transcription of RNA was performed using the T7 (pGEMHE/hD 4.4 ), SP6 (pSP/GIRK1) or T3 (pBScMXT/GIRK2) mMessage mMachine transcription kit (Ambion, Austin, TX). RNA was purified using the RNeasy RNA cleanup kit (Qiagen, Courtaboeuf, France), quantified spectrometrically, diluted to the appropriate concentration in RNAsefree water and stored at x80 xC prior to use.
Isolation and separation of oocytes was performed as previously described (Heusler et al., 2005) . Defolliculated oocytes were injected with y50 nl volume of cRNA solution containing the cRNAs coding for the GIRK1 and GIRK2 channel subunits at a concentration of 20-50 pg cRNA/oocyte each with or without addition of hD 4.4 receptor RNA at 0.5 or 2 ng/ oocyte (no measurable dopamine-induced currents were observed in oocytes injected with 2 ng hD 4.4 receptor RNA alone ; not shown). After injection, oocytes were kept at 17 xC in ND96 solution [96 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 , 5 mM Hepes (pH 7.5) with NaOH] supplemented with 50 mg/l gentamicin. Animals were handled and cared for in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council, 1996) and the European Directive 86/609/EEC, and the protocols were carried out in compliance with French regulations and with local Ethical Committee guidelines for animal research (protocol approved by the Ethics Committee under number 242).
GIRK current recordings
Whole-cell oocyte currents were recorded with the two-electrode voltage-clamp technique using a Geneclamp 500 amplifier (Axon Instruments, Union City, CA, USA), as described previously (Heusler et al., 2005) . Briefly, oocytes were placed in a recording chamber where they were continuously superfused with ND96 solution (2.5-3.5 ml/min). GIRK currents were recorded in high-potassium solution (hK, similar to ND96, but containing 96 mM KCl, 2 mM NaCl) at a holding potential of x70 mV. D 4 receptor ligands dissolved in hK were applied by superfusion. All ligands were applied at a concentration of 1 mM except for aripiprazole and ABT724 (10 mM), in view of their only modest affinity at D 4 receptors.
At the end of each experiment, BaCl 2 (1 mM, dissolved in hK) was applied to quantify the GIRKindependent currents in hK. Evaluation of receptorindependent effects of ligands on GIRK currents was performed as previously described (Heusler et al., 2005) . For drugs exhibiting receptorindependent GIRK current inhibitions in this assay, ligand efficacy values in the assay on receptor activation were corrected for the respective value. The pClamp 8 software (Axon Instruments) was used for data acquisition.
Drugs
The following compounds were obtained commercially : adrenaline, apomorphine HBr, chlorpromazine, dopamine HCl, L741626 (4-(4-chlorophenyl)-1-(1H-indol-3-ylmethyl)piperidin-4-ol), haloperidol, noradrenaline, PD168077 (N-[4-2-cyanophenylpiperazin-1-ylmethyl]-3-methylbenzamide maleate), preclamol, quinelorane, raclopride and spiperone, were purchased from Sigma RBI (St Quentin Fallavier, France). Clozapine and L745870 (3-(4-[4-chlorophenyl] 
Results
Affinity at hD 4.4 receptors
Dopamine exhibited modest affinity at hD 4.4 receptors (pK i =7.05), as previously reported (NewmanTancredi et al., 1997a) . Under present conditions, adrenaline and noradrenaline exhibited low affinities (pK i =6.17 and <5, respectively). Selective dopamine D 4 receptor agonists displayed generally higher affinities with pK i values of 7-8 for PD168077, ABT724 and Ro-10-5824, and of 8.32 for CP226269 (Table 1 , first column).
The selective D 4 receptor antagonists, L745870 and RBI257, as well as the non-selective dopaminergic antagonist, spiperone, displayed high pK i values at hD 4.4 receptors. In contrast, the D 2 /D 3 receptor antagonist, raclopride, the D 3 receptor selective antagonist, S33084 and the preferential D 2 receptor antagonist, L741626, exhibited low affinity at hD 4.4 receptors (pK i values <6.5).
Among the antipsychotics (Table 2 , first column), nemonapride exhibited the highest affinity at hD 4.4 receptors (pK i =9.67) and haloperidol and risperidone displayed marked affinity (pK i values y8) whereas clozapine and olanzapine were less active (pK i y7.3). Recent antipsychotics with combined D 2 -like and 5-HT 1A receptor activity displayed widely differing affinities at hD 4.4 receptors. Thus bifeprunox had high affinity (pK i =9.51) whereas aripiprazole was over 100-fold less potent (pK i =7.34). SLV313, SSR181507 and F15063 exhibited intermediate affinity (pK i 8-9). SLV314, a putative antipsychotic that also exhibits serotonin reuptake inhibition activity, showed high affinity (pK i y9).
The anti-dyskinetic drug, sarizotan, the anti-sexual dysfunction drug, flibanserin, and the D 3 receptor (Figure 1 , Table 1 ). In contrast, the other agonists exhibited lower efficacy : preclamol and apomorphine, as well as the selective D 4 agonists, ABT724 and PD168077, behaved as partial agonists (E max values 37-55 % relative to dopamine). Two other selective agonists, Ro-10-5824 and CP226269 exhibited modest efficacy (E max y20 %).
As expected, the selective D 4 receptor ligands, L745870 and RBI257, and the antipsychotics, clozapine, haloperidol, risperidone and olanzapine, did not stimulate [
35 S]GTPcS binding (Tables 1 and 2 , third column). In contrast, the 'third-generation ' antipsychotics, bifeprunox, SLV313 and F15063, as well as SLV314 and BP897, stimulated [
35 S]GTPcS binding with modest efficacy (E max values 15-29 % ; Fig. 2 Figures 1 and 2) . Sarizotan (33 %) and flibanserin (16 %) exhibited efficacy about two thirds and one third of that of apomorphine, respectively.
The potency (pEC 50 ) of agonists for stimulation of [
35 S]GTPcS binding was correlated with the affinity (pK i ) of the ligands in competition-binding experiments (Figure 3a) . Likewise, the potency of the antagonists (pK B ) for reversal of dopamine-stimulated [ 35 S]GTPcS binding was highly correlated with the affinity (pK i ) of the ligands (Figure 3b) . A parallel set of [ 35 S]GTPcS binding experiments was carried out with a higher NaCl concentration (100 mM), similar to conditions reported previously (Newman-Tancredi et al., 1997a) . Under these conditions, basal [
35 S]GTPcS binding amounted to 6400¡ 400 dpm and increased 2.2-fold to 14300¡1100 dpm with 10 mM dopamine. The apparent efficacy of the agonists (E max values relative to dopamine) was lower than that measured using buffer containing 30 mM NaCl. The difference was most marked for ABT724, CP226269 and Ro-10-5824 : their E max values were approximately halved under high NaCl conditions (Tables 1 and 2 ). In comparison, the E max values of adrenaline and noradrenaline were less markedly affected but the partial agonist activity of flibanserin was no longer detectable. The use of high NaCl conditions also reduced pEC 50 values for several agonists, including CP226269 and Ro-10-5824. In contrast, PD168077 and sarizotan exhibited similar potency under both NaCl conditions (Tables 1 and 2 ). These data suggest that changes in receptor-G-protein interactions induced by NaCl are agonist-dependant, possibly reflecting 'signalling specificity ' of the ligands for specific receptor conformations.
Efficacy at hD 4.4 receptors determined by activation of GIRK currents in Xenopus oocytes
In experiments in which oocytes were injected with 2 ng hD 4.4 receptor cRNA, application of dopamine (1 mM) produced an increase in K + current through coexpressed GIRK channels (Figure 4a ). Under these conditions, dopamine exhibited a pEC 50 of 8.60¡0.13 (Fig. 4b) . Substantial partial agonism was revealed for a series of dopaminergic ligands (Figure 5a ). Thus, apomorphine activated GIRK currents to about 80 % of the effect of dopamine at 1 mM, whereas preclamol as well as the selective D 4 receptor agonists PD168077, ABT724 and CP226269 all had efficacies of about 70 %. It is possible that a higher efficacy of preclamol could have been observed if a higher concentration had been used (e.g. 10 mM instead of 1 mM) but, in any case, it is clear that it has substantial agonist properties in this system. Sarizotan, a 5-HT 1A receptor agonist, and WAY100635, a 5-HT 1A receptor antagonist, induced more modest current activation (y40 % and 30 %, respectively). Slight current activation was also observed with flibanserin (y15 %), and L745870 and RBI257 (y9 % and 6 %, respectively). In separate experiments, the D 4 receptor antagonist, L745870, antagonized the activation of GIRK currents induced by dopamine and the selective agonist, PD168077. Thus dopamine (10 nM) and PD168077 (100 nM) stimulated GIRK currents by 66.3¡9.2 % and 46.2¡2.6 %, respectively, when applied alone, but only by 14.9¡5.5 % and x2.2¡1.2 % in the presence of 1 mM L745870 (n=3 for all values).
As concerns antipsychotics, GIRK current recordings clearly revealed partial agonist properties of F15063, aripiprazole, SLV313 and bifeprunox (E max values y20-30 %), whereas all the other drugs, including haloperidol, clozapine, olanzapine, risperidone, ziprasidone, nemonapride, NDMC and SSR181507 were inactive. The current activation induced by F15063 (1 mM), aripiprazole (10 mM), SLV313 (1 mM) and bifeprunox (1 mM) was antagonized by the D 4 antagonist, RBI257 (1 mM). Residual stimulation in the presence of 1 mM RBI257 was 1.8¡2.4 % for F15063, 2.6¡1.7 % for aripirazole, 3.3¡1.0 % for SLV313 and 0.5¡0.4 % for bifeprunox (n=4-6). SSR181507 (1 mM), on the other hand, antagonized PD168077 (100 nM)-induced GIRK current activation, thus confirming its antagonist properties at hD 4.4 receptors in this model (PD168077 induced 60.3¡7.3 % stimulation when applied alone, but only 17.8¡2.2 % in the presence of SSR181507 ; n=7).
The marked activation observed with the dopaminergic agonists (Figure 5a ) suggested that relatively high levels of hD 4.4 receptor expression were generated by injecting 2.0 ng cRNA/oocyte. For comparison, a lower (0.5 ng) quantity of cRNA was therefore injected into oocytes, leading to a decrease of the pEC 50 for dopamine to 8.03¡0.15, consistent with lower hD 4.4 receptor expression. Under these conditions, the relative E max values for apomorphine and preclamol, as well as for the specific D 4 receptor ligands, PD168077, ABT724, CP226269, L745870 and RBI257 were diminished (Figure 5b ). In addition, the partial agonist activity of F15063 and bifeprunox was reduced to very low levels and the activity of aripiprazole and SLV313 was no longer detectable.
Discussion
The key finding of the present study is that 'third-generation ' antipsychotics currently undergoing clinical or pre-clinical characterization display markedly diverse agonist/antagonist properties in cellular models of dopamine D 4 receptor activation. This has been demonstrated here for two different measures of D 4 receptor signalling : G-protein activation, determined by [
35 S]GTPcS binding, and coupling to GIRK channels, determined by electrophysiological recordings in Xenopus oocytes.
Influence of dopaminergic ligands on G-protein activation
In measures of G-protein activation (with 30 mM NaCl), dopamine robustly stimulated [
35 S]GTPcS binding. In confirmation of previous reports (Czermak et al., 2006 ; Lanau et al., 1997 ; Newman-Tancredi et al., 1997b) , adrenaline and noradrenaline also efficaciously stimulated [
35 S]GTPcS binding albeit with reduced potency (EC 50 values increased by 7-and 19-fold relative to dopamine, respectively). These data indicate that these endogenous agonists are capable of convergent signalling at D 4 receptors at the level of G-protein activation (see also Wedemeyer et al., 2007 for activation of GIRK by dopamine and noradrenaline at D 4 receptors). The profile of action of other ligands was in agreement with their receptor selectivity : the selective D 4 receptor agonists, ABT724, CP226269, PD168077 and Ro-10-5824 modestly stimulated [
35 S]GTPcS binding whereas the antagonists, L745870 and RBI257 did not. The D 2 /D 3 antagonist, raclopride, the preferential D 2 antagonist, L741626 and the selective D 3 antagonist, S33084 (Millan et al., 2000) , were inactive. In contrast, antipsychotics exhibited wide variety of efficacy at D 4 receptors. Thus bifeprunox, F15063, SLV313 and BP897 exhibited (modest) partial agonist properties whereas the established antipsychotics clozapine, haloperidol, olanzapine and risperidone were devoid of agonist properties, as previously reported (Burnstein et al., 2005 ; Newman-Tancredi et al., 1997a ; Patel et al., 2003) . Sarizotan, an antidyskinetic agent, and flibanserin, developed as an antidepressant and antisexual dysfunction drug (Borsini et al., 2002 ; Kuzhikandathil and Bartoszyk, 2006) , both exhibited partial agonist properties at hD 4.4 receptors.
It is important to note that the partial agonists were able to antagonize dopamine-stimulated G-protein activation, bringing [
35 S]GTPcS binding down to the same level as that observed with high concentrations of the drug alone (Figures 1, 2) . Physiologically, such compounds have been described as 'dopamine stabilizers ', activating dopaminergic transmission when it is insufficient and attenuating it when it is excessive (Bolonna and Kerwin, 2005 ; Yocca and Altar, 2006) . A similar 'stabilizing ' influence may apply to D 4 receptors in the areas of cognition/mnesic function increasingly associated with this receptor (see discussion below). However, levels of partial agonism in vitro are highly dependent on experimental conditions, so prudence must be exerted in extrapolating from the present data to physiological responses (cf. Gazi et al., 1999) . Thus, when a higher concentration of sodium (100 mM) is used in the incubation buffers for [
35 S]GTPcS binding, E max values (relative to dopamine) are decreased and a 3-to 5-fold loss of potency (EC 50 values) is seen for most agonists. These data are consistent with the influence of NaCl on opposing receptor-G-protein coupling and therefore decreasing response to agonists (Czermak et al., 2006 ; NewmanTancredi et al., 1997a) and raise the issue of the most physiologically relevant conditions in which to undertake in-vitro studies. Indeed, whilst physiological extracellular sodium concentrations are in the 100 mM range, the [
35 S]GTPcS binding assay reflects GTP/GDP exchange at the Ga subunit of heterotrimeric G-proteins that are located at the intracellular face of plasma membranes where NaCl concentration is much lower (y10 mM), except under neuronal depolarization conditions, when sodium influx transiently increases intracellular NaCl levels. Therefore, a low NaCl concentration may be more 'physiological ' when measuring G-protein activation, as has been discussed previously for 5-HT 1B receptor coupling to Ga-i3 subunits (Newman-Tancredi et al., 2003) . In any case, these data (i) illustrate the difficulty of defining absolute levels of efficacy for agonists in in-vitro studies, and (ii) raise the issue of the amount of receptor activation necessary for pharmacological actions in vivo. Hence, although the precise receptor densities and G-protein subtypes encountered by D 4 receptors in their neuronal microenvironments are unknown, it is possible that even modest partial agonist properties may be sufficient to exert an influence in vivo. This is confirmed by the observation that apomorphine and ABT724 (E max 47 % and 36 %, respectively, Table 1 ) facilitated sexual activity in rodents . Further, PD168077 (E max 39 % in the present system) stimulated ERK phosphorylation in the paraventricular nucleus, a region associated with sexual behaviour (Bitner et al., 2006) . It may be surmised, therefore, that compounds such as bifeprunox, sarizotan, SLV313 and F15063, that possess partial agonist properties (E max 13-32 %) will also influence D 4 activity under physiological conditions. Indeed, F15063 and SLV313 reversed scopolamine-induced memory deficits in a rat social recognition paradigm (Bardin et al., 2006 ; Depoortère et al., 2007) , an action that is blocked by pre-treatment with L745870. Thus, D 4 receptor activation by F15063 and SLV313 appears responsible for their activity in a model of cholinergic deficit, a finding in accordance with the known pro-cholinergic action of SLV313 in neurochemical measures (McCreary et al., 2007) .
Actions of agonists and antagonists on GIRK currents in Xenopus oocytes
In general, the compounds that activated [
35 S]GTPcS binding to CHO-hD 4.4 membranes also increased GIRK channel currents in Xenopus oocytes, demonstrating that they are capable of regulating both of these transduction systems linked to D 4 receptors (cf. Werner et al., 1996) . However, it is interesting to compare in more detail the efficacy of agonists from [
35 S]GTPcS binding experiments, a measure of activation of G-protein Ga subunits, with efficacy determined in GIRK channel activation experiments, a prototypical measure of Gbc subunit activation (Pillai et al., 1998) . Whilst apomorphine exhibited high efficacy in both cases, some other drugs exhibited preferential efficacy for one transduction system vs. the other. Hence, sarizotan exhibited substantial partial agonist efficacy for [ 35 S]GTPcS binding (E max =32 % with 30 mM NaCl conditions), greater than that observed with the selective agonist, CP226289 (E max =23 %). In contrast, sarizotan was less efficacious for activation of GIRK currents (E max <40 %) than CP226289 (E max y70 %). These data suggest that CP226289 may preferentially exert its agonist properties via GIRK channels whereas sarizotan may predominantly influence other G-protein activation pathways and indicate that care must be taken in defining the order of efficacy of ligands according to only a single cellular response. Indeed, the concept of 'functional selectivity ' or 'agonist-directed trafficking of receptor signalling ' (ADTRS ; Kenakin, 2001 ; Perez and Karnik, 2005) whereby different agonists may preferentially influence specific signalling pathways, is reported at several receptors, including 5-HT 2C and dopamine D 2 (Berg and Clarke, 2006 ; Lane et al., 2007) . Aripiprazole has been reported to exhibit ADTRS at dopamine D 2 receptors (Urban et al., 2007) and, in the present study, it exhibited low potency for stimulation of [
35 S]GTPcS binding to CHO cell membranes (Table 2 ) but stimulated GIRK currents to the same extent as bifeprunox or F15063 (Fig. 5) .
However, caution must be exercised when interpreting in-vitro functional responses. Indeed, the influence of the cellular background of the cells (CHO vs. oocytes) may play a role in the differences observed between experimental systems. Further, other authors have reported diverse effects in different functional read-outs. Shapiro et al. (2003) as an antagonist or weak partial agonist depending on the cellular system adopted (Gazi et al., 1999 ; Newman-Tancredi et al., 1997a ; Patel et al., 2003 ; Pillai et al., 1998) . The present data therefore support the notion that this 'antagonist ' actually expresses weak efficacy at D 4 receptors. Similarly, the selective 5-HT 1A receptor antagonist, WAY100635, also stimulated GIRK currents, indicating that it can act as a D 4.4 receptor agonist, as previously reported (Chemel et al., 2006) , although its efficacy and potency are modest ( Figure 5 ; Martel et al., In Press) . Finally, it should be noted that, as in the case of [ 35 S]GTPcS binding studies, experimental conditions are a crucial factor in assessing agonist efficacy. Thus, the amount of cRNA used to transfect the oocytes directly influenced the relative stimulation of GIRK currents, presumably by modifying the amount of D 4 receptor expressed at the cell surface.
Conclusions
The present study demonstrates that a range of dopaminergic ligands and antipsychotics act with differing agonist or antagonist properties at recombinant human D 4.4 receptors. The capacity to activate D 4 receptors in vitro is dependent on experimental conditions such as sodium concentrations for [
35 S]GTPcS binding and the quantity of transfected cRNA for GIRK currents in oocytes. Thus, D 4 receptor stimulation may be sensitive to increases in receptor expression, for example in conditions of pathological up-regulation, as has been observed in post-mortem brain from schizophrenics (Lahti et al., 1998 Extrapolations from the present data to in vivo and/or therapeutic significance should be made with caution, in view of the diverse activity of antipsychotics at multiple receptor subtypes. Nevertheless, whereas older antipsychotics, such as haloperidol, clozapine and risperidone, act as antagonists at D 4 receptors, several 'third-generation ' ligands such as bifeprunox, SLV313, F15063 and aripiprazole (at high concentrations) but not SSR181507, exhibit marked partial agonist activity. Their efficacy corresponds to about one to two thirds of that of apomorphine, ABT724 and PD168077, compounds that have known in-vivo D 4 receptor activity in rodent models of ERK1/2 activation and sexual activity (Bitner et al., 2006 ; Brioni and Moreland, 2006) . Further, the activity of F15063 and SLV313 in a model of memory deficit is blocked by L745870 (Bardin et al., 2006 ; Depoortère et al., 2007) . It may therefore be concluded that even modest in-vitro partial agonist properties will translate in vivo to detectable physiological activity, particularly in regards to cognitive profile (see Introduction) and/or influence on sexual dysfunction.
